Translational Research in Breast Cancer

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 421-438

  Chu, Quyen D ^a   Holm, Neal ^a   Byrnes, Kerry ^a   Li, Benjamin D ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; BLEEDING; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GENE EXPRESSION; HEART DISEASE; HUMAN; HYPERTENSION; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PROGNOSIS; PROTEINURIA; REVIEW; THROMBOEMBOLISM; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; PROTEOMICS;

EID: 41049090252     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.12.006     Document Type: Review

References (68)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10-30
2. Weidner N., Cady B., and Goodson III W.H. Pathologic prognostic factors for patients with breast carcinoma: which factors are important?. Surg Oncol Clin N Am 6 (1997) 415-462
3. Silverstein M.J., Skinner K.A., and Lomis T.J. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 25 (2001) 767-772
4. Isaccs C., Stearns V., and Hayes D.F. New prognostic factors for breast cancer recurrence. Semin Oncol 28 (2001) 53-67
5. van't Veer L., Dai H., van de Vijver M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
6. van de Vijver M., He Y., van't Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
7. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
8. Pawitan Y., Bjöhle J., Amler L., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7 (2005) R953-R964
9. Wang Y., Klijn J., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
10. Foekens J., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 (2006) 1665-1671
11. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
12. Esteva F., Sahin A., Coombes K., et al. Multi-gene RT-PCR assay for predicting recurrence in node-negative breast cancer patients-M.D. Anderson Clinical Validation Study. Breast Cancer Research and Treatment 82 (2003) 17
13. Adjuvant! Online. Decision making tools for health care professionals. Available at: http://www.adjuvantonline.com. Accessed March 3, 2008.
14. Olivotto I., Bajdik C., Ravdin P., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23 (2005) 2716-2725
15. Bogaerts J., Cardoso F., Buyse M., et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3 (2006) 540-551
16. Cronin M., Pho M., Dutta D., et al. Measurement of gene expression in archival paraffin-embedded tissues. Am J Pathol 164 (2004) 35-42
17. Abdullah-Sayani A., Bueno-de-Mesquita J.M., and van de Vijver M.J. Technology insight: tuning into the genetic orchestra using microarrays-limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol 3 (2006) 501-516
18. Nocito A., Kononen J., Kallioniemi O.P., et al. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 94 (2001) 1-5
19. Torhorst J., Bucher C., Kononen J., et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (2001) 2249-2256
20. Kallioniemi O., Wagner U., Kononen J., et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Human Molecular Genetics 10 (2001) 657-662
21. Camp R.L., Charette L.A., and Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80 (2000) 1943-1949
22. Zhao J., Richter J., Wagner U., et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 59 (1999) 4658-4661
23. Richter J., Wagner U., Kononen J., et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157 (2000) 787-794
24. Callagy G., Cattaneo E., Daigo Y., et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12 (2003) 27-34
25. Nocito A., Bubendorf L., Tinner E.M., et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194 (2001) 349-357
26. Makretsov N.A., Huntsman D.G., Nielsen T.O., et al. Hierarchical clustering analysis of tissue micro array immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10 (2004) 6143-6151
27. Abd El-Rehim D.M., Ball G., Pinder S.E., et al. High-throughput protein expression analysis using tissue micro array technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116 (2005) 340-350
28. Sonenberg N. mRNA 5'cap-binding protein eIF4E and control of cell growth. In: Hershey J.W.B., Masters M.B., and Sonenberg N. (Eds). Translational control (1996), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY) 245-269
29. DeBenedetti A., and Harris A.L. eIF4F expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31 (1999) 59-72
30. Rhoads R.E., Joshi-Barve S., and Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects of mRNA discrimination, cellular growth rate, and oncogenesis. Prog Nucleic Acid Res Mol Biol 46 (1993) 183-219
31. Duncan R., Milburn S.C., and Hershey J.W. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF4F suggest a role in translational control. J Biol Chem 262 (1987) 380-388
32. Koromilas A.E., Lazaris-Karatzas A., and Sonenberg N. mRNAs containing extensive secondary stucture in their 5′ non-coding region translate efficiently in cells overxpressing initiation factor eIF-4E. EMBO J 11 (1992) 4153
33. Rosenwald I.B., Lazaris-Karatzas A., Sonenberg N., et al. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 13 12 (1993) 7358
34. Kevil C., DeBenedetti A., Payne D.K., et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 65 6 (1996) 785-790
35. Li Y., DeFatta R., Anthony C., et al. A translationally regulated Tousled Kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 20 (2001) 726-738
36. Li B.D.L., Gruner J.S., Abreo F., et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancere outcome. Ann Surg 235 (2002) 732-739
37. McClusky D., Chu Q., Yu H., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 242 4 (2005) 584-592
38. Campbell J., and Butcher E. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 12 (2000) 336-341
39. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
40. Liang Z., Yoon Y., Votaw J., et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65 (2005) 967-971
41. Holm N., Byrnes K., Li B., et al. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 141 (2007) 53-59
42. Holm N., Byrnes K., McDonald M., et al. Overexpression of chemokine receptor CXCR4 in cancer specimens following neoadjuvant chemotherapy predicts outcome in patients with locally advanced breast cancer (LABC). J Clin Oncol 25 18S (2007) 584s
43. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
44. Kaufmann M., von Minckwitz G., Smith R., et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer. Review and recommendations. J Clin Oncol 21 (2003) 2600-2608
45. Sotiriou C., Powles T., Dowsett M., et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4 (2002) R3
46. Chang J., Wooten E., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
47. Ayers M., Symmans W., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
48. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
49. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 1-12
50. Jessup J., Lively T., and Taube S. Program for the Assessment of Clinical Cancer Tests (PACCT): implementing promising assays into clinical practice. Expert Rev Mol Diagn 5 (2005) 271-273
51. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 (2005) 488-492
52. Simon R., Radmacher M., Dobbin K., et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 (2003) 14-18
53. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
54. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5 (2005) 142-149
55. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 350 (2004) 1814-1816
56. Ntzani E., and Ioannidis J. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362 (2003) 1439-1444
57. Yamauchi H., Stearns V., and Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19 (2001) 2334-2356
58. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplication of the HER2/neu oncogene. Science 235 (1987) 177-182
59. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
60. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
61. Hortobagyi G. Trastuzumab in the treatment of breast cancer. N Engl J Med 353 (2005) 1734-1736 [editorial]
62. Jemal A., Murray T., Samuels A., et al. Cancer statistics. CA Cancer J Clin 53 (2003) 5-26
63. Muss H. Targeted therapy for metastatic breast cancer. N Engl J Med 355 (2006) 2783-2785
64. Wood W.C., Muss H.B., Solin I.J., et al. Malignant tumors of the breast. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles & practice of oncology. 7th edition (2005), Lippincott Williams & Wilkins, Philadelphia 1415-1477
65. Hortobagyi G. Treatment of breast cancer. N Engl J Med 339 (1998) 974-984
66. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
67. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
68. Miller K.D., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). [abstract]. Breast Cancer Res Treat 94 Suppl 1 (2005) S6